These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26878563)

  • 1. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
    Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S
    Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GLP-1 receptor agonists: current state].
    Larger É; Dehghani L; Saatdjian L; Wucher H
    Rev Prat; 2015 Oct; 65(8):1037-8. PubMed ID: 26749700
    [No Abstract]   [Full Text] [Related]  

  • 4. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
    Baron HL
    J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley RE
    Diabetes Technol Ther; 2016 Nov; 18(11):671-673. PubMed ID: 27860501
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.
    McCarthy M
    BMJ; 2015 Dec; 351():h6702. PubMed ID: 26656272
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes.
    Torekov SS; Kipnes MS; Harley RE; Holst JJ; Ehlers MR
    Diabetes Obes Metab; 2011 Jul; 13(7):639-43. PubMed ID: 21362122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 receptor agonist confer target organ protection in type 2 diabetes.
    Bonnet F
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S1-2S2. PubMed ID: 28431665
    [No Abstract]   [Full Text] [Related]  

  • 9. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders.
    Rayner CK; Jones KL; Wu T; Horowitz M
    Diabetes Obes Metab; 2017 Mar; 19(3):309-312. PubMed ID: 27862814
    [No Abstract]   [Full Text] [Related]  

  • 11. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy.
    Nagai Y; Mukai K; Otsuki M; Kimura T; Kozawa J; Nishizawa H; Maeda N; Matsuoka TA; Iwahashi H; Imagawa A; Shimomura I
    Intern Med; 2019 Apr; 58(7):949-953. PubMed ID: 30568127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists.
    Gimeno-Orna JA; Verdes-Sanz G; Borau-Maorad L; Campos-Fernández J; Lardiés-Sánchez B; Monreal-Villanueva M;
    Endocrinol Nutr; 2016 Apr; 63(4):164-70. PubMed ID: 26830854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy.
    Dejgaard TF; Madsbad S
    Diabetes Obes Metab; 2017 Feb; 19(2):153-155. PubMed ID: 27735120
    [No Abstract]   [Full Text] [Related]  

  • 15. An overview of the once-weekly GLP-1 receptor agonists from the pharmacist's perspective.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):3-6. PubMed ID: 32910491
    [No Abstract]   [Full Text] [Related]  

  • 16. The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial.
    Tommerdahl KL; Kendrick J; Bjornstad P
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):905-907. PubMed ID: 35396319
    [No Abstract]   [Full Text] [Related]  

  • 17. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
    Packer M
    J Card Fail; 2018 Feb; 24(2):109-111. PubMed ID: 29305970
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
    Monami M; Marchionni N; Mannucci E
    Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.